

1 **Impact of intraoperative use of venovenous**
2 **extracorporeal membrane oxygenation on the status of**
3 **von Willebrand factor large multimers during single**
4 **lung transplantation**

5
6 Hisashi Oishi^{1*}, Yoshinori Okada¹, Yamato Suzuki¹, Takashi Hirama¹, Yutaka Ejima², Shin-ichi
7 Fujimaki³, Shingo Sugawara³, Noriyuki Okubo³, Hisanori Horiuchi⁴

8
9 ¹Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku
10 University, Sendai, Japan

11 ²Department of Anesthesiology, Tohoku University Hospital, Sendai, Japan

12 ³Department of Laboratory Medicine, Tohoku University School of Medicine, Sendai, Japan

13 ⁴Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer,
14 Tohoku University, Sendai, Japan

15
16 * Corresponding author

17 Email: hisashi.oishi.c7@tohoku.ac.jp (HO)

18
19 Trial registration:

20 UMIN Clinical Trials Registry (UMIN-CTR), UMIN000018135

22 **Abstract**

23 **Purpose**

24 von Willebrand factors (vWFs), hemostatic factors, are produced as large multimers and
25 are shear stress-dependently cleaved to become the appropriate size. A reduction in vWF large
26 multimers develops in various conditions including the use of extracorporeal life support, which
27 can cause excessive-high shear stress in the blood flow and result in hemostatic disorders. The
28 objective of this prospective study was to investigate the impact of venovenous extracorporeal
29 membrane oxygenation (VV ECMO) use on the status of vWF large multimers and hemostatic
30 disorders during single lung transplantation (SLT).

31 **Methods**

32 We prospectively enrolled 12 patients who underwent SLT at our center. Among them,
33 seven patients were supported by VV ECMO intraoperatively (ECMO group) and the remaining
34 five patients underwent SLT without ECMO support (control group). The vWF large multimer
35 index (%) was defined as the ratio of the large multimer proportion in total vWF (vWF large
36 multimer ratio) derived from a patient's plasma to that from the standard human plasma.

37 **Results**

38 The vWF large multimer index at the end of the surgery was significantly lower in the
39 ECMO group than in the control group (112.6% vs. 75.8%, respectively; $p < 0.05$). The
40 intraoperative blood loss and the amounts of intraoperative transfusion products in the ECMO
41 group tended to be greater than those in the control group; however, the differences were not
42 significant.

43 **Conclusion**

44 During SLT, the intraoperative use of VV ECMO caused a decrease in the vWF large
45 multimer index. However, the vWF large multimer index was maintained at > 75% in average at
46 the end of SLT, which did not affect the bleeding complications.

47

48 **Introduction**

49 One of the most severe complications in lung transplantation is perioperative blood loss.
50 Large-volume transfusions of red blood cells (RBCs) and platelets have been reported to be
51 associated with various complications in lung transplant recipients in multiple studies [1].
52 Diamond et al. have identified large-volume RBC transfusion (> 1 L) as a risk factor for grade 3
53 primary graft dysfunction (PGD) in a prospective, multicenter cohort study [2]. Platelet
54 transfusions were shown to be substantial risk factors for the production of anti-human leukocyte
55 antigen (HLA) antibodies [3], which have a potential to cause chronic lung allograft dysfunction
56 (CLAD)[4].

57
58 Intraoperative use of extracorporeal life support (ECLS) is one of the risk factors for the
59 increased amount of bleeding and transfusion in lung transplantation. Among ECLSs,
60 cardiopulmonary bypass (CPB) had been reported to increase blood transfusion due to
61 coagulopathy and inflammatory response [5]. Currently, venoarterial extracorporeal membrane
62 oxygenation (VA ECMO), which is associated with lower blood loss during lung transplant
63 surgeries compared with CPB [6], is preferably used for lung transplant cases unless intracardiac
64 repairs are required [7]. Moreover, venovenous (VV) ECMO has been used as an intraoperative
65 extracorporeal mechanical support for lung transplantation at some lung transplant centers in
66 recent years [8]. We started utilizing VV ECMO in 2015 and reported that VV ECMO could be a
67 choice for intraoperative extracorporeal mechanical support during single lung transplantation
68 (SLT) [9].

69
70 Although the increase in the amount of bleeding during ECLS is primarily due to the use

71 of heparin, recent studies have suggested the involvement of acquired von Willebrand syndrome
72 (AvWS), which is one of the hemostatic disorders. von Willebrand factor (vWF) is a hemostatic
73 factor that is produced and secreted as large multimers by endothelial cells and megakaryocytes.
74 vWF initially forms a huge multimer and is then shear stress-dependently cleaved in the
75 bloodstream by its specific cleaving enzyme ADAMTS13, and then is present as multimers
76 consisting of 2 – 80 vWF monomers [10,11]. The conformation change of A2 domain of vWF by
77 shear stress in the blood flow triggers its cleavage by ADAMTS13. Among the vWF multimers,
78 higher molecular weight multimers (large multimers) are known to play a critical role in
79 hemostasis [10,11]. Lack of ADAMTS13 results in excessive platelet thrombus formation by the
80 function of ultra-large vWF multimers, as seen in patients with hereditary thrombotic
81 thrombocytopenic purpura [12]. On the other hand, some genetic mutations in the vWF A2
82 domain cause a reduction in large multimers and induce a hemostatic disorder by increasing the
83 susceptibility of vWF to cleavage by ADAMTS13 [11]. A reduction in vWF large multimers
84 develops in various other conditions including cardiovascular diseases such as aortic stenosis and
85 the use of ECLS, which can cause excessive-high shear stress in the blood flow and result in
86 hemostatic disorders [11]. This hemostatic disorder caused by excessive cleavage of vWF is
87 defined as AvWS [13].

88
89 Kalbhenn et al. reported that patients treated with VV ECMO support developed AvWS
90 [14]. They have shown that using VV ECMO for pneumonia, ARDS, and so forth can cause
91 unphysiologically high shear stress in the blood stream leading to AvWS within 24 hours after
92 ECMO exposure [14]. However, it remains unclear whether VV ECMO use in a short period of
93 time during lung transplant surgery can causes a decrease of vWF large multimers. The objective
94 of this prospective study was to investigate the impact of VV ECMO use on the status of vWF

95 large multimers and hemostatic disorders during SLT.

96

97 **Patients and Methods**

98 *Patients, blood sample and data collection, and study groups*

99 The Ethics Committee of Tohoku University Graduate School of Medicine approved this
100 retrospective study (IRB approval number, 2016-1-629; protocol number, UMIN000018135), and
101 written informed consent was obtained from all participants. We prospectively enrolled 12
102 patients who would undergo SLT under VV ECMO or without ECMO at Tohoku University
103 Hospital from April 2017 to December 2019 (participant recruitment start date, January 10, 2017;
104 last follow-up date, December 31, 2020) (Fig. 1). The study was carried out in compliance with
105 the 2000 Declaration of Helsinki and its later amendments.

106

107 For the analysis of ADAMTS13 activity and vWF large multimers, blood samples were
108 collected in a tube containing 3.2% sodium citrate from the patients immediately before lung
109 transplantation, before reperfusion (immediately before reperfusion of the lung graft), and at the
110 end of surgery. The plasma of the collected blood was stored at - 80 °C until analysis. The
111 collected data were as follows: pretransplant demographics of the recipients, operative
112 characteristics, postoperative characteristics, and mortality. The level of the pleural adhesion was
113 assessed intraoperatively and graded as follows according to the area of adhesion: severe, 50% to
114 whole thoracic cavity; moderate, partial (only band adhesions) to < 50%; mild, no to partial
115 adhesion; none, no adhesion.

116

117 *ECMO induction procedure and intraoperative management*

118 We established VV ECMO by using right and left femoral veins for the cannulation
119 sites. For the inflow, a 15–22 Fr cannula (CAPIOX EBS, Terumo Corp., Tokyo, Japan or HLS
120 Cannulae, Getinge Group Japan K.K., Tokyo, Japan) was inserted, and the tip was adjusted
121 within a caudal part of the inferior vena cava to minimize the recirculation. For the outflow, a 15–
122 21 Fr cannula (CAPIOX EBS, Terumo Corp., Tokyo, Japan or HLS Cannulae, Bio-Medicus,
123 Medtronic Japan Co., Ltd., Tokyo, Japan) was inserted and the tip was placed at the right atrium
124 using transesophageal echocardiography guidance. The blood flow rate of VV ECMO was started
125 at 50% of the estimated cardiac output of the recipient and adjusted according to the
126 intraoperative results of the arterial blood gas analysis (1.5 – 2.5 L/min). Heparin administration
127 was controlled to target the activated clotting time (ACT) from 160 – 180 s.

128

129 ***Measurement of ADAMTS13 activity and quantitative method for***
130 ***calculation of the vWF large multimer index***

131 ADAMTS13 activity was measured based on the FRETTS-VWF73 assay by SRL Co.
132 (Tokyo, Japan) [15]. We first determined the concentrations of vWF antigen (vWF:Ag) in the
133 standard human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany)
134 by quantitative immunoelectrophoresis using an automatic analyzer. Then, the same amount of
135 vWF:Ag in the plasma of each sample and that in the standard human plasma were analyzed side-
136 by-side by the so-called vWF multimer analysis, which is a western blot analysis under non-
137 reduced conditions. The bands of the 11th and those over the 11th were defined as large
138 multimers. The vWF large multimer proportion was calculated as the densitometric area of those
139 bands using Image J (National Institutes of Health, Bethesda, MD). Then, we determined the
140 parameter, “vWF large multimer index,” as described previously [16]. Briefly, the vWF large

141 multimer index (%) was defined as the ratio of the large multimer proportion in the total vWF
142 (vWF large multimer ratio) derived from a sample to that from the standard human plasma in the
143 adjacent lane [16,17] (Fig. 2). Thus, a patient's vWF large multimer index was expressed as a
144 ratio (percentage) of the standard.

145

146 ***Statistical Analysis***

147 Continuous data are expressed as group mean \pm standard error with ranges. Categorical
148 variables are presented as numbers and percentages. For comparison between the groups,
149 Student's or Welch's *t*-test was used for the parametric data. Mann-Whitney *U* test was used for
150 the nonparametric data. Fisher's exact test or the chi-square test was performed for the
151 categorical values. The ADAMTS13 activity, vWF:Ag, and vWF large multimer index at each
152 time point were analyzed by repeated measures two-way ANOVA. Differences were considered
153 significant at the $p < 0.05$ level. Statistical analyses were performed using Prism 5 (GraphPad
154 Software Inc, La Jolla, Calif) and SPSS Statistics 21.0 for Windows (IBM Corporation, Chicago,
155 IL, USA).

156

157 **Results**

158 ***Study groups and pre-transplant demographics of the recipients***

159 All enrolled patients were followed up until one year after lung transplantation at
160 Tohoku University Hospital, except for one 90-day mortality case. In the present study, we
161 analyzed 5 SLT cases without ECMO use and 7 SLT cases with VV ECMO use. Table 1 shows
162 the pretransplant demographics of the recipients. Recipient age, gender, height, weight, and body

163 mass index (BMI) were similar between the 2 groups. Forced vital capacity (FVC) was
164 comparable between the groups. Because the control group included 3 cases of chronic
165 obstructive pulmonary (COPD), forced expiratory volume in one second (FEV1) in the control
166 group tended to be lower than that in the ECMO group; however, the difference was not
167 statistically significant. There was no significant difference between the 2 groups in prothrombin
168 time–international normalized ratio (PT-INR), activated partial thromboplastin time (APTT), or
169 platelet count.

170

171 *Operative characteristics*

172 Table 2 shows the operative characteristics. There was no significant difference in the
173 operative and cold ischemic time (CIT) between the 2 groups. The mean intraoperative ECMO
174 time in the ECMO group was 487 ± 14 (443 – 557) minutes. The intraoperative blood loss in the
175 ECMO group (1728 ± 734) tended to be greater than that in the control group (774 ± 308);
176 however, the difference was not statistically significant ($p = 0.36$). In the control group, 1 patient
177 (20.0%) intraoperatively required over 1,000 mL of blood transfusion of RBC. On the other hand,
178 3 patients (42.9%) were treated with over 1,000 mL of intraoperative blood transfusion of RBC
179 in the ECMO group. The mean amount of transfusion of RBC in the ECMO group (920 ± 319)
180 tended to be greater than that in the control group (336 ± 210); however, the difference was not
181 statistically significant ($p = 0.28$). In the control group, 1 patient (20.0%) needed over 1,000 mL
182 of fresh frozen plasma (FFP) transfusion. In the ECMO group, the requirement of FFP was over
183 1,000 mL in 2 patients (28.6%). No patient in the control group and 1 patient (14.3%) in the
184 ECMO group required intraoperative transfusion of platelet. Table 2 shows the inflow and
185 outflow cannula sizes in each case in the ECMO group. The cases with relatively smaller outflow

186 cannula (case #5 and 12) tended to require more transfusion products.

187

188 ***Intraoperative ADAMTS13 activity and vWF:Ag***

189 Fig. 3A shows the comparisons of ADAMTS13 activity between the 2 groups in the
190 intraoperative period (before lung transplantation, before reperfusion, and at the end of surgery).

191 There was no significant difference in the ADAMTS13 activity between the ECMO and the
192 control group in the intraoperative period. Fig. 3B shows the comparisons of vWF:Ag between
193 the 2 groups in the intraoperative period. The level of vWF:Ag, representing a total amount of
194 vWF multimers, was expressed as its ratio to that in the standard human plasma because the
195 value of vWF:Ag varies significantly according to the age, ABO blood group, and so forth [18].

196 There was no significant difference in vWF:Ag between the two groups during the intraoperative
197 period.

198

199 ***Intraoperative vWF large multimer index***

200 Fig. 4A shows the vWF large multimer index comparisons between the 2 groups in the
201 intraoperative period. The vWF large multimer index in the control group maintained a level
202 around 100% throughout the perioperative period (mean vWF large multimer index; before LT,
203 $76.7 \pm 10.0\%$; before reperfusion, $100.1 \pm 10.9\%$; end of LT, $112.6 \pm 10.6\%$). On the other hand,
204 the vWF large multimer index in the ECMO group decreased before reperfusion and at the end of
205 LT (mean vWF large multimer index; before LT, $93.8 \pm 7.0\%$; before reperfusion, $74.7 \pm 8.4\%$;
206 end of LT, $75.8 \pm 7.4\%$). The vWF large multimer index at the end of LT was significantly lower
207 in the ECMO group than that in the control group ($p < 0.05$). There were 3 patients who did not
208 receive intraoperative transfusion of FFP in the control group and the ECMO group, respectively.

209 In order to exclude the influence of FFP transfusion on the vWF large multimer indices, we
210 compared the indices in these patients. Fig. 4B shows each patient's intraoperative vWF large
211 multimer index without intraoperative FFP transfusion from the control and the ECMO group.
212 The vWF large multimer index of each case in the control group was 66.8%/86.6%/59.5% at
213 before LT, 89.0%/106.0%/59.5% before reperfusion, and, 89.0%/113.5%/147.7% at the end of
214 LT. The vWF large multimer index of each case in the ECMO group was 84.6%/85.9%/74.2%
215 before LT, 70.6%/65.5%/29.9% before reperfusion, and 92.3%/59.8%/41.8% at the end of LT.
216 Namely, intraoperative vWF large multimer indices decreased to as low as 30–40% in the ECMO
217 group without FFP transfusion whereas that in the control group was maintained at > 60% during
218 SLT surgery.

219

220 *Postoperative characteristics and mortality*

221 Table 3 shows each group's postoperative 30-day, 90-day, and 1-year mortality. No
222 patient was on ECMO at the intensive care unit upon arrival in the control group, and 2 patients
223 (28.6%) were not weaned from VV ECMO in the ECMO group. There was no re-exploration
224 thoracotomy for bleeding in either group. There was no mortality case in the control group within
225 1 year after transplantation. There was one 90-day mortality case in the ECMO group. The cause
226 of the mortality was PGD.

227

228 **Discussion**

229 This is the first study that quantitatively analyzed the intraoperative changes in vWF
230 large multimers in patients who underwent lung transplantation. We demonstrated that vWF large
231 multimer index, which is regarded as the most reliable predictor of AvWS in recent years, was

232 lower in the patients who underwent VV ECMO support during SLT compared to those without
233 ECMO at the end of the surgery. However, the vWF large multimer index was maintained at >
234 75% in average at the end of SLT in the ECMO group, which did not significantly affect the
235 intra- and postoperative outcomes including blood loss, blood transfusion, and re-exploration
236 thoracotomy for bleeding.

237
238 In the present study, the ADAMTS13 activity and vWF:Ag showed no significant
239 change by intraoperative VV ECMO use. On the other hand, there was a significant decrease in
240 the vWF large multimer index at the end of the surgery in SLT. However, the mean vWF large
241 multimer index at the end of surgery was relatively maintained at 75.8% in the ECMO group.
242 The intraoperative blood loss and the required amounts of intraoperative transfusion products in
243 the ECMO group tended to be greater than those in the control group, but the difference was not
244 statistically significant. We previously reported a more severe decrease in the vWF large
245 multimer index in 5 patients with acute cardiovascular diseases treated with VA ECMO [10].
246 These patients exhibited vWF large multimer indices of 20.8% at 24 hours, 51.0% at 23 hours,
247 27.6% at 47 hours, 28.8% at 19 hours, and 31.0% at 82 hours after VA ECMO initiation [10], and
248 2 of the 5 patients had massive bleeding events, while the oozing type of bleeding at the skin of
249 the sites of cannula insertion was observed in all 5 patients, indicating an apparent hemostatic
250 disorder [10].

251
252 The results regarding AvWS in our study were also quite different from those in a
253 previous study reported by Kalbhenn et al. They demonstrated that patients receiving VV ECMO
254 support for respiratory failure were all diagnosed with AvWS, as shown by the ratio of the
255 collagen-binding capacity (vWF:CB) to vWF:Ag decreasing to about 0.25 in average (vWF:CB/

256 vWF:Ag, normal: > 0.7). They also reported that 17 of the 18 patients developed bleeding
257 complications from 3 to 30 days after ECMO[14]. The different results in our study from those
258 in previous studies may be primarily explained by the short duration of time of ECMO use in our
259 study. The relatively low threshold for the use of intraoperative FFP transfusion in our cohort, the
260 thicker venous outflow cannulas in VV ECMO compared to those in VA ECMO in general [10],
261 and the lower blood flow rate of 1.5 – 2.5 L/min in the present study compared with that in VA
262 ECMO used for patients with severe respiratory failure may also be responsible for the
263 difference.

264
265 We acknowledge that there are several limitations in the present study. First, it was a
266 single-center analysis with a small number of patients, and thus we cannot accurately compare
267 the outcome of each group. Second, there were a few patients receiving an intraoperative
268 transfusion of FFP in both groups. Therefore, an accurate comparison of the vWF large multimer
269 indices was impossible. Whereas we compared the vWF large multimer indices in the patients
270 without intraoperative FFP transfusion between the control and the ECMO group, the number of
271 patients was not enough for statistical analysis. Third, we were not able to enroll a large enough
272 number of patients to undergo lung transplantation under CPB or VA ECMO in this study, which
273 would be a future challenges.

274
275 In conclusion, intraoperative use of VV ECMO for SLT caused a decrease in the vWF
276 large multimer index. However, the vWF large multimer index in the present study remained at
277 an average of > 75% and was as low as 30–40% at the end of surgery with VV ECMO, and its
278 impact on bleeding complications was limited.

279

280 **Acknowledgments**

281 This research was supported by Japan Agency for Medical Research and Development
282 under Grant Number 20ek0109370h0003. A part of this study was conducted as collaborative
283 research with Sysmex Corporation (Kobe, Japan).

284 **References**

- 285 [1] Pena JJ, Bottiger BA, Miltiades AN. Perioperative Management of Bleeding and Transfusion
286 for Lung Transplantation. *Semin Cardiothorac Vasc Anesth* 2020;24:74–83.
- 287 [2] Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical risk
288 factors for primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med*
289 2013;187:527–34.
- 290 [3] Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, et al.
291 Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year
292 experience in 441 patients. *Chest* 2013;144:226–33.
- 293 [4] Lau CL, Palmer SM, Posther KE, Howell DN, Reinsmoen NL, Massey HT, et al. Influence of
294 Panel-Reactive Antibodies on Posttransplant Outcomes in Lung Transplant Recipients.
295 *Transplantation* 2000;69:1520–4.
- 296 [5] Dalibon N, Geffroy A, Moutafis M, Vinatier I, Bonnette P, Stern M, et al. Use of
297 Cardiopulmonary Bypass for Lung Transplantation: A 10-Year Experience. *J Cardiothorac Vasc*
298 *Anesth* 2006;20:668–72.
- 299 [6] Machuca TN, Collaud S, Mercier O, Cheung M, Cunningham V, Kim SJ, et al. Outcomes of
300 intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung
301 transplantation. *J Thorac Cardiovasc Surg* 2015;149:1152–7.
- 302 [7] Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Zacharoulis D. Extracorporeal
303 membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-
304 analysis. *Gen Thorac Cardiovasc Surg* 2018;66:38–47.
- 305 [8] Moreno Garijo J, Cypel M, McRae K, Machuca T, Cunningham V, Slinger P. The Evolving
306 Role of Extracorporeal Membrane Oxygenation in Lung Transplantation: Implications for

- 307 Anesthetic Management. *J Cardiothorac Vasc Anesth* 2019;33:1995–2006.
- 308 [9] Oishi H, Matsuda Y, Ejima Y, Toyama H, Hirama T, Watanabe T, et al. Changes in
309 haemodynamics during single lung transplantation under venovenous extracorporeal membrane
310 oxygenation. *Interact Cardiovasc Thorac Surg* 2022;35:ivac101.
- 311 [10] Tamura T, Horiuchi H, Obayashi Y, Fuki M, Imanaka M, Kuroda M, et al. Acquired von
312 Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane
313 oxygenation. *Cardiovasc Interv Ther* 2019;358–63.
- 314 [11] Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von willebrand
315 syndrome associated with cardiovascular diseases. *J Atheroscler Thromb* 2019;26:303–14.
- 316 [12] M Furlan, R Robles, M Solenthaler, M Wassmer, P Sandoz BL. Deficient Activity of von
317 Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic
318 Purpura. *Blood* 1997;89:3097–103.
- 319 [13] Alsidawi S, Couto M, López-Candales A. Acquired Von Willebrand Syndrome In Aortic
320 Stenosis: Case Report And Review. *Bol Asoc Med P R* 2015;107:86–8.
- 321 [14] Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis
322 of Acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients
323 treated with ECMO therapy. *J Atheroscler Thromb* 2015;22:265–71.
- 324 [15] Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETs-VWF73, a first fluorogenic
325 substrate for ADAMTS13 assay. *Br J Haematol* 2005;129:93–100.
- 326 [16] Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M, et al. Unexpectedly high
327 prevalence of acquired von Willebrand syndrome in patients with severe aortic stenosis as
328 evaluated with a novel large multimer index. *J Atheroscler Thromb* 2015;22:1115–23.
- 329 [17] Sakatsume K, Saito K, Akiyama M, Sasaki K, Kawatsu S, Takahashi G, et al. Association
330 between the severity of acquired von Willebrand syndrome and gastrointestinal bleeding after

331 continuous-flow left ventricular assist device implantation. Eur J Cardio-thoracic Surg
332 2018;54:841–6.
333 [18] Wang Z, Dou M, Du X, Ma L, Sun P, Cao H, et al. Influences of ABO blood group, age and
334 gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13
335 levels in a Chinese population. PeerJ 2017;2017.
336

337 **Tables**

338 **Table 1. Pretransplant demographics**

339

| | Control group (<i>n</i> = 5) | ECMO ^a group (<i>n</i> = 7) | <i>P</i> value |
|--|----------------------------------|--|----------------|
| Age (years) | 48.4 ± 3.8 (34 – 57) | 47.1 ± 4.1 (23 – 59) | 0.85 |
| Gender (M/F) | 3 / 2 | 4 / 3 | 0.92 |
| Height (cm) | 164.4 ± 3.2 (153.5 – 175.0) | 162.4 ± 2.6 (150.4 – 173.0) | 0.66 |
| Weight (kg) | 50.5 ± 6.4 (35.0 – 75.0) | 55.6 ± 6.9 (30.0 – 91.8) | 0.64 |
| BMI (kg/m ²) ^b | 18.5 ± 2.0 (13.0 – 26.4) | 20.7 ± 2.0 (13.3 – 30.7) | 0.50 |
| Indication | | | |
| IPF ^c | 0 (0%) | 4 (57.1%) | |
| COPD ^d | 3 (60.0%) | 0 (0%) | |
| LAM ^e | 1 (20.0%) | 2 (28.6%) | |
| CTD-ILD ^f | 1 (20.0%) | 1 (14.3%) | |
| Pulmonary function test | | | |
| FVC ^g (% predicted) | 55.1 ± 5.0 (46.4 – 76.0) | 50.9 ± 8.0 (23.6 – 85.0) | 0.71 |
| FEV1 ^h (% predicted) | 35.1 ± 7.5 (17.8 – 57.6) | 43.7 ± 6.5 (26.3 – 78.4) | 0.44 |
| PT-INR ⁱ | 0.99 ± 0.02 (0.93 – 1.04) | 1.00 ± 0.02 (0.99 – 1.00) | 0.79 |
| APTT ^j (sec) | 32.2 ± 2.7 (27.4 – 33.9) | 30.3 ± 1.0 (27.4 – 33.9) | 0.53 |
| Platelet count (x 10 ³ /μl) | 258 ± 12 (221 – 301) | 240 ± 13 (189 – 282) | 0.39 |

Values are expressed as mean ± standard error (range) or number (%). ^aECMO, extracorporeal membrane oxygenation (ECMO). ^bBMI, body mass index. ^cIPF, idiopathic pulmonary fibrosis. ^dCOPD, chronic obstructive pulmonary. ^eLAM, lymphangioleiomyomatosis. ^fCTD-ILD, connective tissue disease-associated interstitial lung disease. ^gFVC, forced vital capacity. ^hFEV1, forced expiratory volume in one second. ⁱPT-INR, prothrombin time–international normalized ratio. ^jAPTT, activated partial thromboplastin time.

340

341 **Table 2. Operative characteristics**

342

| Case # | Group | OP ^a time (min) | CIT ^b (min) | Intra-OP ECMO time ^c (min) | Cannula size (Fr) | | Intra-OP blood loss (mL) | Pleural adhesion grade ^f | Intra-OP blood transfusion | | |
|--------|---------|----------------------------|------------------------|---------------------------------------|-------------------|---------|--------------------------|-------------------------------------|----------------------------|-----------------------|---------------|
| | | | | | Inflow | Outflow | | | RBC ^e (mL) | FFP ^d (mL) | Platelet (mL) |
| 4 | Control | 365 | 361 | - | - | - | 249 | None | 0 | 0 | 0 |
| 6 | Control | 383 | 456 | - | - | - | 644 | Severe | 280 | 480 | 0 |
| 7 | Control | 366 | 457 | - | - | - | 307 | None | 0 | 0 | 0 |
| 8 | Control | 452 | 480 | - | - | - | 2122 | Severe | 1400 | 1200 | 0 |
| 9 | Control | 430 | 564 | - | - | - | 550 | Moderate | 280 | 0 | 0 |
| 1 | ECMO | 504 | 457 | 459 | 22 | 22 | 2332 | None | 1680 | 2880 | 0 |
| 2 | ECMO | 423 | 453 | 517 | 19.5 | 18 | 547 | Moderate | 280 | 0 | 0 |
| 3 | ECMO | 356 | 447 | 455 | 21 | 21 | 869 | None | 560 | 480 | 0 |
| 5 | ECMO | 482 | 656 | 557 | 21 | 15 | 6228 | Severe | 1960 | 1440 | 200 |
| 10 | ECMO | 380 | 457 | 443 | 21 | 16.5 | 748 | Mild | 0 | 0 | 0 |
| 11 | ECMO | 409 | 550 | 485 | 21 | 16.5 | 177 | None | 0 | 0 | 0 |
| 12 | ECMO | 468 | 539 | 492 | 16.5 | 15 | 1198 | None | 1960 | 480 | 0 |
| | | <i>P</i> = 0.29 | <i>P</i> = 0.34 | | | | <i>P</i> = 0.36 | | <i>P</i> = 0.28 | <i>P</i> = 0.44 | |

^aOP, operative. ^bCIT, cold ischemia time. ^cECMO, extracorporeal membrane oxygenation (ECMO). ^dRBC, red blood cell. ^eFFP, fresh frozen plasma. ^fPleural adhesion grade: severe, 50% to whole thoracic cavity; moderate, partial (only band adhesions) to < 50%; mild, no to partial adhesion; none, no adhesion.

343

344 **Table 3. Postoperative characteristics and mortality**

345

| | Control group (<i>n</i> = 5) | ECMO ^a group (<i>n</i> = 7) |
|---|----------------------------------|--|
| ECMO on ICU ^b arrival | 0 (0%) | 2 (28.6%) |
| Re-exploration thoracotomy for bleeding | 0 (0%) | 0 (0%) |
| Mortality | | |
| 30-day | 0 (0%) | 0 (0%) |
| 90-day | 0 (0%) | 1 (14.3%) ^b |
| 1-year | 0 (0%) | 0 (0%) |

Values are expressed as numbers (%). ^aECMO, extracorporeal membrane oxygenation. ^bICU, intensive care unit. ^cThe cause of death was primary graft dysfunction.

346

347 **Figure legends**

348 **Figure 1. Flow diagram for study participation**

349 SLT, single lung transplantation; VA ECMO, venoarterial extracorporeal membrane
350 oxygenation; VV ECMO, venovenous extracorporeal membrane oxygenation.

351 352 **Figure 2. Quantification method for calculation of the von Willebrand factor (vWF) large** 353 **multimer index**

354 We first determined the concentrations of von Willebrand factor (vWF) in the standard
355 human plasma (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) and in
356 each sample simultaneously by western blot analysis under reduced conditions followed by
357 densitometry analysis. Bands 1–5 (starting from the lowest molecular weight band) were
358 classified as low, 6–10 as medium, and those >10 as large multimers. The vWF large multimer
359 proportion was calculated as the densitometric area of those bands. The vWF large multimer
360 index (%) was defined as the ratio of the large multimer proportion in the total vWF (vWF large
361 multimer ratio) derived from a sample to that from the standard human plasma in the adjacent
362 lane.

363 364 **Figure 3. Intraoperative ADAMTS13 activity and von Willebrand factor antigen (vWF:Ag)**

365 For intraoperative analysis, blood samples were collected from the patients immediately
366 before lung transplantation, before reperfusion (immediately before reperfusion of the lung graft),
367 and at the end of surgery. These time points are indicated as “Before LT,” “Before reperfusion,”
368 and “End of LT,” respectively (LT, lung transplantation). The data are represented as a box and
369 whiskers plot. White boxes represent the control group (n = 5, white boxes with stripes for

370 ADAMTS13 activity, white boxes with dots for vWF:Ag), and gray boxes are the extracorporeal
371 membrane oxygenation (ECMO) group (n = 7, gray boxes with stripes for ADAMTS13 activity,
372 gray boxes with dots for vWF:Ag). The middle horizontal line represents the median. The upper
373 and lower borders of the box represent the upper and lower quartiles. The upper and lower
374 whiskers represent the maximum and minimum values.

375 (A) Intraoperative ADAMTS13 activity. There was no significant difference in the ADAMTS13
376 activity between the control and ECMO group in the perioperative period. The mean
377 ADAMTS13 activity before LT (control group vs. ECMO group), $41.6 \pm 8.2\%$ vs. $45.2 \pm 10.1\%$,
378 $p > 0.05$; before reperfusion, (control group vs. ECMO group), $37.6 \pm 8.0\%$ vs. $41.7 \pm 9.3\%$, $p >$
379 0.05 ; at the end of LT, (control group vs. ECMO group), $35.3 \pm 5.5\%$ vs. $47.4 \pm 8.5\%$, $p > 0.05$.

380 (B) Intraoperative vWF:Ag. There was no significant difference in the vWF:Ag between the
381 control and ECMO group in the intraoperative period. The mean vWF:Ag activity at before LT
382 (control group vs. ECMO group), $114.4 \pm 40.1\%$ vs. $181.2 \pm 42.8\%$, $p > 0.05$; before reperfusion,
383 (control group vs. ECMO group), $157.5 \pm 34.1\%$ vs. $136.9 \pm 27.9\%$, $p > 0.05$; at the end of LT,
384 (control group vs. ECMO group), $158.9 \pm 37.0\%$ vs. $137.0 \pm 25.4\%$, $p > 0.05$.

385

386 **Figure 4. Intraoperative von Willebrand factor (vWF) large multimer index**


387 For intraoperative analysis, blood samples were collected from the patients right before
388 lung transplantation, before reperfusion (immediately before reperfusion of the lung graft), and at
389 the end of surgery. These time points are indicated as “Before LT,” “Before reperfusion,” and
390 “End of LT,” respectively (LT, lung transplantation).

391 (A) Intraoperative vWF large multimer index. The data are represented as a box and whiskers
392 plot. White boxes represent the control group (n = 5), and gray boxes are the extracorporeal
393 membrane oxygenation (ECMO) group (n = 7). The middle horizontal line represents the median.

394 The upper and lower borders of the box represent the upper and lower quartiles. The upper and
395 lower whiskers represent the maximum and minimum values. The mean von Willebrand factor
396 (vWF) large multimer index at before LT (control group vs. ECMO group), $76.7 \pm 10.0\%$ vs.
397 $93.8 \pm 7.0\%$, $p > 0.05$; at before reperfusion, (control group vs. ECMO group), $100.1 \pm 10.9\%$ vs.
398 $74.7 \pm 8.4\%$, $p > 0.05$; at end of LT, (control group vs. ECMO group), $112.6 \pm 10.6\%$ vs. $75.8 \pm$
399 7.4% , $p < 0.05$.

400 (B) Intraoperative vWF large multimer index: comparison between the cases without fresh frozen
401 plasma (FFP) transfusion. There were 3 patients in the control group and the ECMO group,
402 respectively who did not receive intraoperative transfusion of FFP. The vWF large multimer
403 index of each case in the control group was 66.8%/86.6%/59.5% before LT,
404 89.0%/106.0%/59.5% before reperfusion, and, 89.0%/113.5%/147.7% at the end of LT. The vWF
405 large multimer index of each case in the ECMO group was 84.6%/85.9%/74.2% before LT,
406 70.6%/65.5%/29.9% before reperfusion, and 92.3%/59.8%/41.8% at the end of LT.

Figure 1




medRxiv preprint doi: <https://doi.org/10.1101/2023.02.07.23285614>; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1

Figure 2

$$\text{vWF large multimer ratio} = \frac{\text{Large multimer area}}{\text{Total area}}$$




medRxiv preprint doi: <https://doi.org/10.1101/2023.02.07.23285614>; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

$$\text{vWF large multimer index (\%)} = \frac{\text{vWF large multimer ratio of a sample plasma}}{\text{vWF large multimer ratio of the control plasma}}$$

Figure 2


Figure 3



medRxiv preprint doi: <https://doi.org/10.1101/2023.02.07.23285614>; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3

Figure 4



medRxiv preprint doi: <https://doi.org/10.1101/2023.02.07.23285614>; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 4